Aura Biosciences, Inc.
AURA
$7.63
-$0.02-0.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.32M | 6.91M | 5.34M | 5.73M | 5.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.07M | 34.87M | 27.24M | 27.91M | 28.61M |
| Operating Income | -48.07M | -34.87M | -27.24M | -27.91M | -28.61M |
| Income Before Tax | -45.61M | -33.67M | -25.54M | -26.10M | -26.97M |
| Income Tax Expenses | 29.00K | 11.00K | 15.00K | 26.00K | 48.00K |
| Earnings from Continuing Operations | -45.64M | -33.69M | -25.56M | -26.13M | -27.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.64M | -33.69M | -25.56M | -26.13M | -27.02M |
| EBIT | -48.07M | -34.87M | -27.24M | -27.91M | -28.61M |
| EBITDA | -47.81M | -34.59M | -26.97M | -27.63M | -28.33M |
| EPS Basic | -0.48 | -0.50 | -0.38 | -0.40 | -0.47 |
| Normalized Basic EPS | -0.30 | -0.31 | -0.24 | -0.25 | -0.29 |
| EPS Diluted | -0.48 | -0.50 | -0.38 | -0.40 | -0.47 |
| Normalized Diluted EPS | -0.30 | -0.31 | -0.24 | -0.25 | -0.29 |
| Average Basic Shares Outstanding | 94.86M | 67.45M | 67.10M | 65.94M | 58.02M |
| Average Diluted Shares Outstanding | 94.86M | 67.45M | 67.10M | 65.94M | 58.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |